- Is biontech stock worth buying?
- What will happen to biontech stock when the pandemic ends?
- What happened to biontech on Friday?
- How big is biontechs comirnaty revenues?
- Is it too late to buy biontech stock?
- Is biontech efficiently growing its dividend?
- Where can I buy biontech (bntx)?
- What is biontechs stock symbol?
- Whats behind biontechs strong quarterly earnings growth?
- Is biontech a publicly traded company?
- What is biontech doing with the €50 million loan?
Is biontech stock worth buying?
Still, BioNTech has some of the things biotechs need to be successful: a pipeline full of promising candidates, and tons of cash to fund clinical studies without relying on dilutive forms of financing. Thats why I believe this biotech stock is worth buying, at least for those investors willing to hold on to shares beyond the next couple of years.
What will happen to biontech stock when the pandemic ends?
Even if the pandemic comes to a screeching halt after this year, BioNTech wont let all the money its already generated from its coronavirus vaccine go to waste. And if revenue and earnings drop substantially once the pandemic ends, its evident that the money already brought in from the vaccine has had a major impact on the companys future.
What happened to biontech on Friday?
What happened Shares of BioNTech (NASDAQ: BNTX) are sinking 8.7% as of 11:07 a.m. ET on Friday. The biggest news for the company was positive.
How big is biontechs comirnaty revenues?
For fiscal 2021, BioNTech said it expects between 16 billion euros and 17 billion euros (or between $18 billion and $19.1 billion) in revenue from Comirnaty. The companys total revenue as of the nine-month period ended Sept. 30 was 13.4 billion euros ($15.1 billion).
Is it too late to buy biontech stock?
The biggest argument for why it might be too late to buy BioNTech stock is that it doesnt have any products on the market besides Comirnaty, and sales of the vaccine are unlikely to go significantly higher.
Is biontech efficiently growing its dividend?
BioNTech does not have a long track record of dividend growth. In the past three months, BioNTech insiders have not sold or bought any company stock. Only 14.34% of the stock of BioNTech is held by institutions. Earnings for BioNTech are expected to decrease by -17.10% in the coming year, from $39.23 to $32.52 per share.
Where can I buy biontech (bntx)?
Shares of BNTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioNTechs stock price today?
What is biontechs stock symbol?
BioNTech trades on the NASDAQ under the ticker symbol BNTX. Who are BioNTechs major shareholders? BioNTechs stock is owned by a number of institutional and retail investors.